Pralay Mukhopadhyay

TL;DR: The data supported a slight decrease in durvalumab clearance with time and suggested that it may be associated with a decrease in nonspecific protein catabolic rate among cancer patients who benefit from therapy.

TL;DR: The log-rank test is most powerful under proportional hazards (PH) as mentioned in this paper, however, non-PH patterns are often observed in clinical trials, such as in immuno-oncology; therefore, alternative methods ar...

TL;DR: In this paper, three categories of testing methods were evaluated, including weighted log-rank tests, Kaplan-Meier curve-based tests, and combination tests (including Breslow test, Lee's combo test, and MaxCombo test).

TL;DR: Standard parametric models fitted to the initial ATLANTIC DCO generally underestimated longer-term OS, compared with the later DCO, and Cure, parametric mixture and response-based landmark models predicted that larger proportions of patients with metastatic non-small cell lung cancer receiving IO treatments may experience long-term survival, which was more in keeping with the observed data.

TL;DR: In this article, a log-rank test was used to evaluate the risk of nonproportional hazard in a clinical trial where NPH is a possibility and loss of power and clear description of treatment differences are key issues in designing and analyzing clinical trials.